NEW YORK (Reuters Health)—About two-thirds of patients with ulcerative colitis (UC) had mucosal healing by the end of induction treatment with the infliximab biosimilar CT-P13, according to results of the first prospective study to evaluate this. CT-P13 is the first biosimilar monoclonal antibody of reference infliximab (Remicade) approved in Europe and several other countries where…
Articles by Natasha Yetman
Regeneron Pain Drug Clears Late-Stage Trial
(Reuters)—Drugmaker Regeneron Pharmaceuticals Inc. said on Monday its experimental drug to treat moderate to severe osteoarthritis pain was successful in a late-stage study. The drug, fasinumab, was tested on 421 patients with a history of inadequate pain relief or intolerance to current painkillers. Fasinumab binds to nerve growth factor (NGF) proteins and block their activity,…
France Gets G7 to Discuss Global Regulation of Medicine Prices
PARIS (Reuters)—France will press its G7 partners this month to launch an “irreversible” process to control the prices of new medicines, part of a global drive to make life-saving drugs more affordable, three sources told Reuters. President Francois Hollande said in March he would push for the international regulation of drugs prices when he meets…
Ustekinumab Improves Spondylitis in Patients with Psoriatic Arthritis
NEW YORK (Reuters Health)—The anti-interleukin (IL)-12/IL-23 monoclonal antibody ustekinumab improves signs and symptoms of spondylitis in patients with psoriatic arthritis, according to a post-hoc analysis of data from the PSUMMIT-1 and PSUMMIT-2 trials. “This treatment did seem to have a benefit on axial symptoms,” Dr. Arthur Kavanaugh from the University of California San Diego, La…
Anthem CEO Backs Obamacare Insurance Exchanges & Sees Possible Growth
(Reuters)—Health insurer Anthem Inc. on Wednesday said the Obamacare individual insurance exchanges are not as profitable as it originally expected, but it is not planning to exit like competitor UnitedHealth Group. Anthem Chief Executive Officer Joseph Swedish said the company had picked up more exchange customers than it expected during the first quarter and that…
Patients with Mental Illness Fare Worse after Hip Surgery
(Reuters Health)—People with psychiatric illnesses are more likely to have complications after hip replacement surgery, according to a recent analysis. This added risk is something doctors and patients should discuss in advance, the study team writes in The Journal of Arthroplasty, March 17. Previous studies have linked depression and other mental illnesses to greater complications…
Ryan Wants to End Obamacare Cost Protections for Sick Consumers
WASHINGTON (Reuters)—U.S. House of Representatives Speaker Paul Ryan (R-Wis.) called on Wednesday for an end to Obamacare‘s financial protections for people with serious medical conditions, saying these consumers should be placed in state high-risk pools. In election-year remarks that could shed light on an expected Republican healthcare alternative, Ryan said existing federal policy that prevents…
Triple Therapy with Methotrexate Effective, Cheaper in RA
NEW YORK (Reuters Health)—The combination of methotrexate, sulphasalazine and hydroxychloroquine is similar in effect as methotrexate plus biologic therapy for patients with rheumatoid arthritis (RA), according to a new network meta-analysis. “Thus, for most patients, this low-cost combination of medications should probably be tried before moving onto biologic therapy, either as initial treatment or as…
Abaloparatide May Boost BMD in Older Women with Osteoporosis
NEW YORK (Reuters Health)—The investigational drug abaloparatide may help postmenopausal women increase their bone mineral density (BMD) and reduce their risk of fracture, new industry research suggests. “What was surprising and very important about this study was that, although some drugs for osteoporosis don’t work across all patient subgroups, abaloparatide provided persistent protection against fracture…
CMS Commences 45-Day Open Payments Review & Dispute Period
On April 1, the Centers for Medicare and Medicaid Services (CMS) announced the beginning of the 45-day Open Payments Review and dispute period, which will conclude on May 15. After the review period concludes, on June 30, CMS will publish 2015 payment data along with updates to the 2013 and 2014 data. If you are…
- « Previous Page
- 1
- …
- 64
- 65
- 66
- 67
- 68
- …
- 97
- Next Page »